BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28534659)

  • 1. Healthcare costs among men with favorable risk prostate cancer managed with observation strategies versus immediate treatment in an integrated healthcare system.
    Kariburyo F; Wang Y; Cheng IE; Wang L; Morgenstern D; Asner I; Xie L; Meadows E; Danella J
    J Med Econ; 2017 Aug; 20(8):825-831. PubMed ID: 28534659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study.
    Kariburyo F; Wang Y; Cheng IE; Wang L; Morgenstern D; Xie L; Meadows E; Danella J; Cher ML
    BMC Urol; 2018 Jun; 18(1):55. PubMed ID: 29866100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study].
    Reinhold T; Dornquast C; Börgermann C; Weißbach L
    Urologe A; 2016 Dec; 55(12):1573-1585. PubMed ID: 27822603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer.
    Thomsen FB; Røder MA; Jakobsen H; Langkilde NC; Borre M; Jakobsen EB; Frey A; Lund L; Lunden D; Dahl C; Brasso K
    Clin Genitourin Cancer; 2019 Aug; 17(4):e814-e821. PubMed ID: 31196798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.
    Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM
    Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
    van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
    BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive analysis of cost of an active surveillance cohort compared to radical prostatectomy as primary treatment for prostate cancer.
    Pozo C; Hernández V; Capitán C; de la Peña E; Fernández-Conejo G; Martínez MDM; Del Riego S; Pérez-Fernández E; Llorente C
    World J Urol; 2019 Jul; 37(7):1297-1303. PubMed ID: 30276542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active Surveillance for Men with Intermediate Risk Prostate Cancer.
    Agrawal V; Ma X; Hu JC; Barbieri CE; Nagar H
    J Urol; 2021 Jan; 205(1):115-121. PubMed ID: 32658588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.
    Seiler D; Randazzo M; Klotz L; Grobholz R; Baumgartner M; Isbarn H; Recker F; Kwiatkowski M
    BJU Int; 2012 Jul; 110(2):195-200. PubMed ID: 22093744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
    Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
    Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
    Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
    Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generalizability of the Prostate Cancer Intervention Versus Observation Trial (PIVOT) Results to Contemporary North American Men with Prostate Cancer.
    Dalela D; Karabon P; Sammon J; Sood A; Löppenberg B; Trinh QD; Menon M; Abdollah F
    Eur Urol; 2017 Apr; 71(4):511-514. PubMed ID: 27638094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy.
    Banerji JS; Hurwitz LM; Cullen J; Wolff EM; Levie KE; Rosner IL; Brand TC; LʼEsperance JO; Sterbis JR; Porter CR
    Urol Oncol; 2017 May; 35(5):234-242. PubMed ID: 28110975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic analysis of conservative management versus active treatment for men with localized prostate cancer.
    Perlroth DJ; Bhattacharya J; Goldman DP; Garber AM
    J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):250-7. PubMed ID: 23271781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer.
    Vetterlein MW; Löppenberg B; Karabon P; Dalela D; Jindal T; Sood A; Chun FK; Trinh QD; Menon M; Abdollah F
    Cancer; 2017 Sep; 123(17):3241-3252. PubMed ID: 28472547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active surveillance for localized prostate cancer: an analysis of patient contacts and utilization of healthcare resources.
    Thomsen FB; Berg KD; Røder MA; Iversen P; Brasso K
    Scand J Urol; 2015 Feb; 49(1):43-50. PubMed ID: 25363612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
    Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
    JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
    Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
    Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.